A class of natural product, these are heavily post-translationally modified peptides containing sulfide bonds which are synthesised by bacteria as a defence mechanism. They have been shown to have activity as antibacterials, in cystic fibrosis and in cancer.

Exploitation of these molecules has been held back by the complexity of their structure: almost invariably they are isolated from bacterial culture. This limits scientists’ ability to make structural changes to optimise their properties. New Path has developed technologies to enable the efficient total and semi- synthesis of analogues to allow optimisation of activity and pharmokinetics.

Antimicrobial Resistance in Gram Negative Bacteria

Lanthipeptides have been known for decades to have antibacterial activity against gram-positive bacteria, with no observed development of resistance. Using our technology platform to access fully synthetic analogues, New Path are developing analogues which also have activity against gram-negative bacteria as a new medicine in the fight against antimicrobial resistant bacteria.


New Path is also exploring lanthipeptide interactions with cancer cell membranes. We are collaborating  with Prof Michael Wakelam at the Babraham Institute to investigate their potential as a new approach in oncology.